In the last trading session, 1.28 million shares of the Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) were traded, and its beta was 0.72. Most recently the company’s share price was $26.19, and it changed around -$2.05 or -7.26% from the last close, which brings the market valuation of the company to $3.24B. ARWR currently trades at a discount to its 52-week high of $42.48, offering almost -62.2% off that amount. The share price’s 52-week low was $20.67, which indicates that the current value has risen by an impressive 21.08% since then. We note from Arrowhead Pharmaceuticals Inc.’s average daily trading volume that its 10-day average is 0.8 million shares, with the 3-month average coming to 1.62 million.
Arrowhead Pharmaceuticals Inc. stock received a consensus recommendation rating of Hold, based on a mean score of 1.57. If we narrow it down even further, the data shows that 0 out of 4 analysts rate the stock as a Sell; another 1 rate it as Overweight. Among the rest, 3 recommended ARWR as a Hold, whereas 0 deemed it a Buy, and 0 rated it as Underweight. Arrowhead Pharmaceuticals Inc. is expected to report earnings per share of -$0.16 for the current quarter.
Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) trade information
Instantly ARWR has showed a red trend with a performance of -7.26% at the end of last trading. The performance over the last five days has remained in the red territory. The company’s shares are currently down -14.41% year-to-date, but still down -6.10% over the last five days. On the other hand, Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) is -27.41% down in the 30-day period. We can see from the shorts that 9.2 million shares have been sold at a short interest cover period of 5.1 day(s).
The consensus price target as assigned by Wall Street analysts is $63.86, which translates to bulls needing to increase their stock price by 58.99% from its current value. Analyst projections state that ARWR is forecast to be at a low of $31 and a high of $90.
Arrowhead Pharmaceuticals Inc. (ARWR) estimates and forecasts
Arrowhead Pharmaceuticals Inc. share prices are performing particularly well not compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -2.53 percent over the past six months and at a -40.63% annual growth rate that is well below the industry average of 8.70%. Moreover, analysts have decided to roll up on their fiscal year 2024 revenue estimates. The rating firms predict that it will loss -135.60% in revenue this quarter, and will report an increase of 34.40% in the next quarter. The year-over-year growth rate is expected to be -42.20%, down from the previous year.
Consensus estimates provided by 10 financial analysts predict the company will bring in an average of $63.87 million in revenue for the current quarter. 11 analysts expect Arrowhead Pharmaceuticals Inc. to make $29.52 million in revenue for the quarter ending Jun 2024.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -24.19%. Arrowhead Pharmaceuticals Inc. earnings are expected to increase by -40.09% in 2024, but the outlook is positive 7.33% per year for the next five years.
ARWR Dividends
Arrowhead Pharmaceuticals Inc.’s next quarterly earnings report is expected to be released around April 30 and May 06.
Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 4.49% of Arrowhead Pharmaceuticals Inc. shares, and 65.27% of them are in the hands of institutional investors. The stock currently has a share float of 68.34%. Arrowhead Pharmaceuticals Inc. stock is held by 370 institutions, with Blackrock Inc. being the largest institutional investor. By Jun 29, 2023, it held 11.95% of the shares, which is about 12.81 million shares worth $456.85 million.
Vanguard Group Inc, with 10.24% or 10.97 million shares worth $391.25 million as of Jun 29, 2023, holds the second largest percentage of outstanding shares.
iShares Core S&P Midcap ETF and Vanguard Total Stock Market Index Fund were the top two Mutual Funds as of Sep 29, 2023. The former held 3.35 million shares worth $90.08 million, making up 3.13% of all outstanding shares. On the other hand, Vanguard Total Stock Market Index Fund held roughly 3.23 million shares worth around $115.06 million, which represents about 3.01% of the total shares outstanding.
